Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Matsuzaki, Junko ^a   Tsuji, Takemasa ^a,b   Luescher, Immanuel F ^c   Shiku, Hiroshi ^d   Mineno, Junichi ^e   Okamoto, Sachiko ^e   Old, Lloyd J ^b   Shrikant, Protul ^a,f   Gnjatic, Sacha ^b,g   Odunsi, Kunle ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d MIE UNIVERSITY   (Japan)

^e TAKARA BIO INC   (Japan)

^f MAYO GRADUATE SCHOOL   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CTAG1B PROTEIN, HUMAN; GAMMA INTERFERON; MEMBRANE PROTEIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ANIMAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; CYTOTOXICITY; DRUG EFFECTS; FEMALE; HELPER CELL; HUMAN; IMMUNOLOGY; JURKAT CELL LINE; METABOLISM; OVARY TUMOR; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; INTERFERON-GAMMA; JURKAT CELLS; MEMBRANE PROTEINS; MICE, SCID; OVARIAN NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84943601242     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14896     Document Type: Article

References (41)

1. Pardoll, D. M. and Topalian, S. L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588-594 (1998).
2. Bevan, M. J. Helping the CD8(+ ) T-cell response. Nat Rev Immunol 4, 595-602 (2004).
3. Kumamoto, Y., Mattei, L. M., Sellers, S., Payne, G. W. and Iwasaki, A. CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input. Proc Natl Acad Sci USA 108, 8749-8754 (2011).
4. Talmadge, J. E. Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact. Semin. Cancer Biol. 21, 131-138 (2011).
5. Nishimura, T. et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190, 617-627 (1999).
6. Quezada, S. A. et al. Tumor-reactive CD4(+ ) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637-650 (2010).
7. Xie, Y. et al. Naive tumor-specific CD4(+ ) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207, 651-667 (2010).
8. Muranski, P. et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362-373 (2008).
9. Davis, I. D. et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+ ) and CD8(+ ) T cell responses in humans. Proc. Natl. Acad. Sci. USA 101, 10697-10702 (2004).
10. Valmori, D. et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl. Acad. Sci. USA 104, 8947-8952 (2007).
11. Jager, E. et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl. Acad. Sci. USA 103, 14453-14458 (2006).
12. Odunsi, K. et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl. Acad. Sci. USA 104, 12837-12842 (2007).
13. Matsuzaki, J. et al. Nonclassical Antigen-Processing Pathways Are Required for MHC Class II-Restricted Direct Tumor Recognition by NY-ESO-1-Specific CD4+ T Cells. Cancer Immunol Res 2, 341-350 (2014).
14. Braumuller, H. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361-365 (2013).
15. Shrikant, P., Khoruts, A. and Mescher, M. F. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11, 483-493 (1999).
16. Williams, M. A. and Bevan, M. J. Effector and memory CTL differentiation. Ann Rev Immunol 25, 171-192 (2007).
17. Feau, S. et al. The CD4(+ ) T-cell help signal is transmitted from APC to CD8(+ ) T-cells via CD27-CD70 interactions. Nat Commun 3, 948 (2012).
18. Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29, 917-924 (2011).
19. Chodon, T. et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 20, 2457-2465 (2014).
20. Hunder, N. N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358, 2698-2703 (2008).
21. Odunsi, K. et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl. Acad. Sci. USA 104, 12837-12842 (2007).
22. Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A. and Morgan, R. A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 66, 8878-8886 (2006).
23. Brown, D. M. Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy. Cell Immunol 262, 89-95 (2010).
24. de Goer de Herve, M. G. et al. Direct CD4 help provision following interaction of memory CD4 and CD8 T cells with distinct antigen-presenting dendritic cells. J Immunol 185, 1028-1036 (2010).
25. Butler, M. O. et al. Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help. PloS one 7, e30229 (2012).
26. Chin, Y. E. et al. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272, 719-722 (1996).
27. Houghton, A. N., Thomson, T. M., Gross, D., Oettgen, H. F. and Old, L. J. Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J. Exp. Med. 160, 255-269 (1984).
28. Le, Y. S. et al. Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers. Exp Mol Med 34, 18-26 (2002).
29. Mohan, J. F. et al. Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat Immunol 11, 350-354 (2010).
30. Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002).
31. Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924 (2011).
32. Till, B. G. et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271 (2008).
33. Robbins, P. F. et al. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Longterm Follow-up and Correlates with Response. Clin Cancer Res 21, 1019-1027 (2015).
34. Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546 (2009).
35. Kerkar, S. P. et al. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J Immunother 34, 343-352 (2011).
36. Huang, X. et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 16, 580-589 (2008).
37. Odunsi, K. et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc. Natl. Acad. Sci. USA 109, 5797-5802 (2012).
38. Tsuji, T., Altorki, N. K., Ritter, G., Old, L. J. and Gnjatic, S. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. J Immunol 183, 4800-4808 (2009).
39. Aldener-Cannava, A. and Olerup, O. HLA-DPB1 typing by polymerase chain reaction amplification with sequence-specific primers. Tissue antigens 57, 287-299 (2001).
40. Tsuji, T. et al. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106, 470-476 (2005).
41. Okamoto, S. et al. A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression. Mol Ther Nucleic Acids 1, e63 (2012).